Screening of antinuclear antibodies: comparison between enzyme immunoassay based on nuclear homogenates, purified or recombinant antigens and immunofluorescence assay

被引:30
作者
Bernardini, S
Infantino, M
Bellincampi, L
Nuccetelli, M
Afeltra, A
Iori, R
Biroccio, A
Urbani, A
Federici, G
机构
[1] Univ Roma Tor Vergata, Dept Internal Med, I-00133 Rome, Italy
[2] Univ Roma Tor Vergata, Dept Lab Med PTV, I-00133 Rome, Italy
[3] Bambino Gesu IRCCS Hosp, Rome, Italy
[4] Univ G DAnnunzio, Dept Biomed Sci, Chieti, Italy
[5] Univ Fdn G DAnnunzio, CeSI, Chieti, Italy
关键词
antinuclear antibody; immunofluorescence; enzyme immunoassay;
D O I
10.1515/CCLM.2004.235
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 [基础医学];
摘要
Current clinical practice considers antinuclear antibody (ANA) testing as a screening test; this has a major impact on laboratory work with a growing volume of analyses that need to be performed rapidly, to maintain good specificity and sensitivity. Ongoing discussions have been raised in order to identify the best technology to use in ANA screening, taking into account both clinical and economical implications. The aim of our study was to compare three different enzyme immunoassays (EIA) with immunofluorescence (IF) assay in order to identify which test is better for use as a screening test. The study was performed on 473 sera and the three different EIA tests were based on nuclear homogenates from HeLa cells, purified antigens from HEp-2 cells and recombinant antigens, respectively. The concordance between EIAANA and IFANA techniques, determined by the kappa statistic, was acceptable, but not complete, and discrepancies between both EIApositive/IFnegative samples and IFpositive/EIAnegative were found. Both methods show interesting diagnostic abilities, however, the IFANA assay seems to be the first choice test in a wellstandardized immunofluorescence laboratory with experienced microscopists, whereas the EIA test might be useful especially in largescale ANA screening.
引用
收藏
页码:1155 / 1160
页数:6
相关论文
共 21 条
[1]
Development of autoantibodies before the clinical onset of systemic lupus erythematosus [J].
Arbuckle, MR ;
McClain, MT ;
Rubertone, MV ;
Scofield, RH ;
Dennis, GJ ;
James, JA ;
Harley, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (16) :1526-1533
[2]
Multicenter evaluation study on a new HEp2 ANA screening enzyme immune assay [J].
Bayer, PM ;
Bauerfeind, S ;
Bienvenu, J ;
Fabien, N ;
Frei, PC ;
Gilburd, B ;
Heide, KG ;
Hoier-Madsen, M ;
Meroni, PL ;
Monier, JC ;
Monneret, G ;
Panzeri, P ;
Shoenfeld, Y ;
Spertini, F ;
Wiik, A .
JOURNAL OF AUTOIMMUNITY, 1999, 13 (01) :89-93
[3]
Clinical significance of antinuclear antibodies - Comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays [J].
Emlen, W ;
ONeill, L .
ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1612-1618
[4]
Antinuclear antibody determination in a routine laboratory [J].
Feltkamp, TEW .
ANNALS OF THE RHEUMATIC DISEASES, 1996, 55 (10) :723-727
[5]
FRIOU GJ, 1957, J CLIN INVEST, V36, P890
[6]
GENTH E, 1996, CLIN IMMUNOLOGY, P119
[7]
Antinuclear antibodies (ANA) screening by enzyme immunoassay with nuclear HEp-2 cell extract and recombinant antigens:: analytical and clinical evaluation [J].
González, C ;
Guevara, P ;
Alarcón, I ;
Hernando, M ;
Navajo, JA ;
González-Buitrago, JM .
CLINICAL BIOCHEMISTRY, 2002, 35 (06) :463-469
[8]
Hayashi N, 2001, CLIN CHEM, V47, P1649
[9]
Homburger HA, 1998, ARCH PATHOL LAB MED, V122, P993
[10]
Jaskowski TD, 1996, AM J CLIN PATHOL, V105, P466